Sanofi ADR
NASDAQ: SNY · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
Updated 2026-06-04
Sanofi ADR (SNY) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $74.27B | $69.00B | $71.99B | $80.05B | $85.26B | $100.67B | $100.41B | $96.06B | $97.39B | $102.32B | $104.67B | $99.81B | $111.41B | $112.63B | $114.41B | $120.24B | $126.72B | $126.46B | $132.80B | $126.81B |
| Cash & equivalents | $1.15B | $1.71B | $540.00M | $689.00M | $5.77B | $1.93B | $6.38B | $8.26B | $7.34B | $9.15B | $10.27B | $10.31B | $6.92B | $9.43B | $13.91B | $10.10B | $12.74B | $8.71B | $7.44B | $7.66B |
| Current assets | $12.16B | $12.55B | $15.40B | $17.53B | $20.04B | $20.79B | $22.80B | $23.91B | $23.43B | $24.93B | $26.69B | $26.35B | $24.65B | $28.94B | $33.70B | $30.56B | $34.03B | $30.66B | $42.59B | $30.95B |
| Total liabilities | $28.45B | $24.28B | $26.92B | $31.60B | $31.98B | $44.30B | $42.94B | $39.02B | $41.12B | $44.11B | $46.95B | $41.57B | $52.37B | $53.40B | $51.16B | $51.21B | $51.57B | $52.11B | $54.94B | $55.10B |
| Current liabilities | $10.28B | $9.67B | $9.35B | $10.96B | $10.09B | $13.56B | $13.86B | $13.93B | $13.03B | $16.82B | $16.43B | $15.46B | $17.38B | $20.39B | $19.25B | $21.30B | $23.96B | $24.19B | $29.16B | $28.35B |
| Long-term debt | $5.94B | $5.45B | $5.81B | $8.54B | $8.88B | $16.21B | $14.13B | $14.35B | $28.44B | $12.97B | $16.82B | $14.33B | $22.01B | $20.13B | $19.75B | $17.12B | $14.86B | $14.35B | $11.79B | $14.25B |
| Shareholder equity | $45.60B | $44.54B | $44.87B | $48.19B | $53.10B | $56.20B | $57.33B | $56.90B | $56.12B | $58.05B | $57.55B | $58.07B | $59.03B | $59.23B | $63.11B | $68.68B | $74.78B | $74.04B | $77.51B | $71.38B |
| Retained earnings | $44.06B | $47.27B | $45.63B | $48.32B | $50.17B | $53.45B | $52.90B | $53.07B | $52.55B | $52.01B | $51.48B | $52.86B | $53.11B | $51.78B | $60.15B | $63.01B | $66.73B | $67.50B | — | — |
| Accounts receivable | $7.08B | $6.84B | $7.01B | $7.95B | $8.32B | $10.19B | $9.60B | $8.85B | $9.01B | $8.85B | $9.05B | $8.68B | $9.35B | $10.08B | $9.95B | $9.79B | $10.75B | $11.04B | $10.63B | $396.83M |
| Inventory | $3.66B | $3.73B | $3.59B | $4.44B | $5.02B | $6.05B | $6.38B | $6.35B | $6.56B | $6.52B | $6.89B | $6.82B | $7.48B | $7.99B | $8.35B | $8.71B | $8.96B | $9.67B | $9.43B | $22.69B |
| Goodwill | $28.47B | $27.20B | $28.16B | $29.73B | $31.93B | $38.58B | $38.07B | $37.13B | $39.20B | $39.56B | $40.29B | $40.26B | $44.23B | $44.52B | $44.36B | $48.06B | $49.89B | $49.40B | $43.38B | $41.30B |
Frequently asked questions
What is Sanofi ADR's revenue?
Sanofi ADR's trailing twelve-month revenue is $47.35B, and consensus projects about $65.90B by 2030. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is SNY?
In its most recent fiscal year, SNY ran a gross margin of 72.07%, an operating margin of 20.54%, and a net margin of 16.72%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does SNY generate?
SNY produced $10.14B in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is SNY's balance sheet healthy?
SNY holds $7.66B in cash and equivalents against $14.25B in long-term debt, on $71.38B of shareholder equity. That debt is best read against the cash flow the business throws off each year.